As state-level bans and federal enforcement actions restrict access to kratom and concentrated 7-hydroxymitragynine (7-OH) extracts across the United States, daily users face sudden dependency crises and acute withdrawal symptoms, according to reports from Playa del Carmen, Mexico. In response to these shifting regulatory landscapes, medical facilities such as Ibogaine by David Dardashti are proposing specialized ibogaine treatment protocols designed to serve as a rapid medical off-ramp for displaced individuals.
Addressing Kratom Displacements and Central Nervous System Recovery
Thousands of regular kratom consumers now face abrupt cessation as authorities target the herbal substance and its concentrated derivatives. Rather than directing these individuals toward traditional Medication-Assisted Treatment (MAT)—which often trades a daily herbal habit for multi-year synthetic opioid dependence—clinical protocols utilizing ibogaine aim to reset central nervous system receptors directly. According to clinic founder David Dardashti, the treatment clears alkaloid binding sites in a single therapeutic window to eliminate physical cravings without creating secondary pharmaceutical dependencies.
To safely process the complex multi-alkaloid profile unique to kratom, the Playa del Carmen facility employs proprietary mathematical modeling software. This system calculates a patient’s total alkaloid exposure against individual biological variables. By doing so, clinicians determine exact washout periods and customized ibogaine dosing under continuous cardiac monitoring, shifting the therapeutic approach from generic administration to data-driven precision medicine.
Advocating for Right to Try Policy Expansions
Alongside clinical interventions, David Dardashti is championing the expansion of “Right to Try” policy frameworks within the United States. This advocacy campaign encourages lawmakers to grant treatment-resistant patients stateside access to regulated ibogaine therapy. Proponents argue that prohibition alone fails to solve public health challenges, often driving vulnerable populations toward unregulated illicit markets.
This domestic policy push parallels established medical frameworks found among several international allies. According to global health policy summaries:
- New Zealand: Recognizes ibogaine as a formal medical treatment and regulates it strictly by prescription.
- South Africa: Classifies ibogaine as a prescription medicine under Schedule 6 regulations while leaving kratom largely unregulated.
- Canada: Regulates ibogaine under prescription drug lists while forbidding internal sales of kratom.
- Australia: Regulates ibogaine under Schedule 4 medical standards, while maintaining a strict ban on kratom under Schedule 9.
- United Kingdom: Controls ibogaine and prohibits the supply of kratom via the Psychoactive Substances Act.
“Prohibition without a medically viable off-ramp creates immediate public health emergencies,” states David Dardashti. “By pairing mathematical precision dosing with progressive Right to Try policies, global health leaders can provide a safe, permanent exit strategy for individuals caught in the crossfire of shifting substance regulations.”
Toward International Regulatory Alignment
The stark contrasts in how nations regulate substances like kratom and ibogaine highlight an urgent need for synchronized international policy. While countries like Australia enforce total bans, and nations like South Africa maintain more permissive or distinct frameworks, health authorities face mounting pressure to cooperate. Establishing a unified international coalition could standardize medical screening, clinical dosing protocols, and cross-border transport logistics for neuro-restorative care, ensuring that individuals displaced by sudden regulatory bans have access to safe medical exit strategies.
Worth a look